![UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis – UCB](https://healthandfitnessniche.com/wp-content/uploads/J6_coFbogxhRI9iM864NL_liGXvsQp2AupsKei7z0cNNfDvGUmWUy20nuUhkREQyrpY4bEeIBucs0-w300-rw.webp "UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis – UCB")
- UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis UCB
- UCB rapidly bolsters blockbuster potential for Bimzelx with 3 new FDA approvals FiercePharma
- UCB gets expanded FDA…
[ad_2]
Source link
